Pharma Healthcare Newsletter - August 14 to August 18, 2017

This week, “Government aims to boost domestic manufacturing of drugs, levy a cap on trade margin, crackdown on unfair marketing practices and limit 'loan licensing' by pharma companies, according to the draft national pharmaceutical policy.”

Aug 19, 2017 10:08 IST India Infoline News Service

Top news:

National pharma policy draft suggests vital medicines at reasonable prices

Government aims to boost domestic manufacturing of drugs, levy a cap on trade margin, crackdown on unfair marketing practices and limit 'loan licensing' by pharma companies, according to the draft national pharmaceutical policy. Read more
 
IPO Alert: Aster DM Healthcare refiles DRHP with SEBI

Aster DM Healthcare has refiled draft red herring prospectus (DRHP) with the market regulator, Securities and Exchange Board of India (SEBI). Earlier, the company had filed DRHP with SEBI on June 24, 2016. Read more
 
Suven Life Sciences secures process patents in Europe, Japan and New Zealand

The company has received patents for new chemical entities (NCEs) which are for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2034. Read more
 
Zydus Cadila gets USFDA nod for Telmisartan and Hydrochlorothiazide Tablets

Zydus Cadila announced that the company has received the final approval from the USFDA to market Telmisartan and Hydrochlorothiazide Tablets USP, in the strengths of 40mg/ 12.5 mg, 80 mg/12.5 mg and 80mg/25 mg, on Thursday. Read more

Related Story